Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Feliza Mirasol is the science editor for 

Videos

Roquette Pharma Solutions' Christine Mya-San, global account manager, highlights the most significant pharma ingredients at play over the past year and discusses future ingredient innovation.

DCAT Week 2025: Key Ingredients in Pharmaceutical Manufacturing

PharmTech Group spoke with Alison Moore, chief technical officer, Codexis to find out the latest about the RNA therapy market and to get perspective on how enzymatic RNA synthesis is used to synthesize RNA molecules.


DCAT Week 2025: Enzymatic RNA Synthesis

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

In an interview with Pharmaceutical Technology®, Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.

Industry Outlook 2025: A Busy Time Ahead

Articles

The partnership aims to develop and commercialize a novel checkpoint inhibitor for immuno-oncology applications.

Shilpa Biologicals and mAbTree Biologics to Collaborate on Novel Immuno-Oncology Asset

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

The Member Company Announcement Forum is the kickoff event of the annual DCAT Week in New York City, which is being held from March 17–20.

DCAT Member Companies Present Latest News to Start DCAT Week 2025

Webcasts

Webinar Date/Time: Wed, Mar 26, 2025 1:30 PM EDT

Long acting PLGA complex parenterals and IVIVC development

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Exosomes, polymeric nanoparticles, and DNA nanostructures offer many potential advantages.

Organic Nanoparticle-Based Drug-Delivery Systems as Alternatives to Lipid Nanoparticles

CHMP gave its opinion and a recommendation for marketing authorization to Fabhalta (iptacopan), an oral, Factor B inhibitor of the alternative complement pathway.

Novartis Treatment for C3G Gets Positive Opinion from EMA

Mike Hennessy Jr. is the President and CEO of 

Artificial intelligence, among other technological advances, is pushing innovation boundaries.

Pushing Tech Boundaries

Jaypirca (pirtobrutinib) has received a conditional marketing authorization from EMA for mantle cell lymphoma. The drug was approved in the United States in 2023 for several indications.

Drug Development

Research into Cold Cancers Heating Up

Development of Gamma-Delta T-Cell Therapies

QbD for Small-Molecule Continuous Process Development